Study Summary
This trial will last for 52 weeks and have different groups of people testing different treatments, all of which are blinded. There will be check-ups every 4 weeks and at the end of the study. There will be an equal number of males and females in every group.
- Non-alcoholic Fatty Liver Disease (NAFLD)
Video Summary
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 52 weeks
Trial Safety
Safety Progress
Trial Design
5 Treatment Groups
2.5mg
1 of 5
5.0 mg
1 of 5
1.0 mg
1 of 5
10 mg
1 of 5
Placebo
1 of 5
Experimental Treatment
Non-Treatment Group
337 Total Participants · 5 Treatment Groups
Primary Treatment: VK2809 · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 75 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| North Carolina | 28.6% |
| Louisiana | 14.3% |
| New York | 14.3% |
| Other | 42.9% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| Viking Clinical Site 307 | 50.0% |
| Viking Clinical Site 108 | 50.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 28.6% |
| Did not meet criteria | 71.4% |
Why did patients apply to this trial?
- "There was a NYC location when I was reading about the trial"
- "I’m hoping to find a medication that will help my fatty liver disease."
How many prior treatments have patients received?
| 0 | 100.0% |
Frequently Asked Questions
Are the subjects of this experiment restricted to adults?
"The eligibility requirements for this study say that participants must be aged 18 to 75. Out of the 24 clinical trials currently underway, none are for patients younger than 18 whereas 204 are looking specifically for elderly patients." - Anonymous Online Contributor
How many participants are involved in this research?
"A total of 337 patients that meet the required inclusion criteria must participate in this clinical trial. Patients can receive treatment from various locations, two of which are Viking Clinical Site 211 in West Des Moines, Iowa and Viking Clinical Site 214 in North Little Rock, Arkansas." - Anonymous Online Contributor
Has there been previous research on VK2809?
"VK2809 was first studied in 2019 at Viking Clinical Site 144. Since then, there have been 242 completed studies with 1 active trial. A large number of these trials are being conducted out of West Des Moines, Iowa." - Anonymous Online Contributor
Who would be an ideal candidate for this experiment?
"The research team is looking for 337 participants that have a fatty liver and are between 18-75 years old." - Anonymous Online Contributor
Is this clinical trial being run in a considerable number of medical clinics across Canada?
"Currently, this study is being conducted at Viking Clinical Site 211 in West Des Moines, Iowa; Viking Clinical Site 214 in North Little Rock, Arkansas; Viking Clinical Site 216 in Glendale, Arizona; and 78 other research sites." - Anonymous Online Contributor
Is this a new clinical trial?
"VK2809 has been under investigation since 2019 when Viking Therapeutics, Inc. ran the first clinical trial with 337 participants. After successful completion of Phase 2 in 2019, there is only one active study for VK2809 being sponsored by Viking Therapeutics, Inc.." - Anonymous Online Contributor
Are there still slots available for individuals who wish to participate in this research project?
"That is accurate. The most recent update on clinicaltrials.gov was from October 31st, 2022 and it indicates that the study is still recruiting patients. This research project was initially posted on November 15th, 2019 and it plans to admit 337 total participants across 78 different locations." - Anonymous Online Contributor
What is the most severe adverse reaction to VK2809?
"As this is a Phase 2 trial, there is some evidence to support VK2809's safety. However, as there is no data backing up the efficacy of VK2809 at this time, it received a score of 2." - Anonymous Online Contributor